Related Experiment Video
Updated: Sep 10, 2025
Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
Prenatal Management of Spinal Muscular Atrophy in the Era of Genetic Screening and Emerging Opportunities in In Utero
Silvestar Mežnarić1, Andrej Belančić1, Valentino Rački2,3
1Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
Insights
Early diagnosis and prenatal treatment for spinal muscular atrophy (SMA) are crucial for improving infant outcomes. Advances in genetic testing and fetal therapies offer new hope for this severe neuromuscular disorder.
Area of Science:
- Neurology
- Genetics
- Perinatal Medicine
Background:
- Spinal muscular atrophy (SMA) is a severe genetic neuromuscular disorder and a primary cause of infant mortality.
- Early diagnosis and intervention significantly improve outcomes for SMA patients.
- Prenatal screening and diagnostics are expanding, creating opportunities for early detection and in utero treatment.
Purpose of the Study:
- To review current evidence on prenatal management of SMA.
- To focus on diagnostic strategies, fetal genetic testing, and emerging fetal therapies.
- To critically address ethical, regulatory, and economic considerations of in utero interventions.
Main Methods:
- Narrative review of existing literature.
- Synthesis of current evidence on diagnostic approaches (invasive and non-invasive).
- Evaluation of experimental prenatal treatment modalities for SMA.
Main Results:
- Advances in disease-modifying therapies necessitate early diagnosis for optimal outcomes.
- Prenatal genetic screening and molecular diagnostics are increasingly available.
- Fetal therapy for SMA is an emerging area with potential for transformative impact.
Conclusions:
- Integrating in utero strategies could reshape perinatal medicine for genetic neurodegenerative disorders.
- Early diagnosis, fetal intervention, and genetic counseling are key to optimizing care.
- While challenges exist, fetal therapy for SMA is nearing clinical feasibility, requiring further research and trials.
Abstract:
Spinal muscular atrophy (SMA) is a severe autosomal recessive neuromuscular disorder and a leading genetic cause of infant mortality. Advances in disease-modifying therapies have significantly improved outcomes when treatment is initiated early, underscoring the importance of timely diagnosis. With the growing availability of prenatal genetic screening and high-resolution molecular diagnostics, opportunities for early detection, and potentially in utero intervention, are rapidly expanding. This narrative review synthesizes current evidence on the prenatal management of SMA, focusing on diagnostic strategies, the clinical application of fetal genetic testing, and the emerging potential of fetal therapy. We explore both invasive and non-invasive diagnostic approaches and evaluate experimental prenatal treatment modalities, while critically addressing the associated ethical, regulatory, and economic considerations. As the field progresses, integrating in utero strategies into clinical care may reshape perinatal medicine and offer transformative potential for genetic neurodegenerative disorders diagnosed before birth. The convergence of early diagnosis, fetal intervention, and personalized genetic counseling will be central to optimizing care pathways and outcomes in the era of precision medicine. Although significant challenges remain, the translation of fetal therapy into routine clinical practice is approaching feasibility. Future clinical trials, anchored in definitive prenatal diagnosis, will be essential, with benefits potentially outweighing the inherent procedural risks.
